Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.

Attard, G; Reid, AH; Auchus, RJ; Hughes, BA; Cassidy, AM; Thompson, E; Oommen, NB; Folkerd, E; Dowsett, M; Arlt, W; +1 more... de Bono, JS; (2012) Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. The Journal of clinical endocrinology and metabolism, 97 (2). pp. 507-16. ISSN 0021-972X DOI: https://doi.org/10.1210/jc.2011-2189

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1210/jc.2011-2189

Abstract

Share

Download

Full text not available from this repository.

Downloads

View details

Metrics & Citations


Google Scholar